Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 21;17(18):3084.
doi: 10.3390/cancers17183084.

Real World Data on the Efficacy of Brigatinib in ALK-Positive Non-Small Cell Lung Cancer: A Single-Center Experience

Vesna Ćeriman Krstić  1   2 , Natalija Samardžić  1   2 , Mihailo Stjepanović  1   2 , Spasoje Popević  1   2 , Tatjana Adžić-Vukičević  1   2 , Sofija Glumac  1   3 , Ruža Stević  1   4 , Dragana Marić  1   2 , Marta Velinović  2 , Milena Jovanović  1   3 , Branislav Ilić  1   2 , Milija Gajić  2 , Nikola Čolić  1   4 , Katarina Lukić  4 , Brankica Milošević Maračić  5 , Slavko Stamenić  2 , Ivana Sekulović Radovanović  2 , Jelena Milin Lazović  6
Affiliations

Real World Data on the Efficacy of Brigatinib in ALK-Positive Non-Small Cell Lung Cancer: A Single-Center Experience

Vesna Ćeriman Krstić et al. Cancers (Basel). .

Abstract

Introduction: Lung cancer remains the leading cause of cancer death among all cancers. The discovery of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations led to an increased survival rate in patients with locally advanced and metastatic non-small cell lung cancer (NSCLC). Results of the ALTA 1L study showed superior outcomes for patients treated with brigatinib compared to patients treated with crizotinib. Background: We conducted research including 23 patients with ALK-positive lung adenocarcinoma who were treated with brigatinib in first or further lines of therapy. The median follow-up was 22 months (4-66 months). Results: There were no significant differences in patient population between the first and further lines of treatment regarding sex distribution (p = 0.692), smoking status (p = 0.554), ECOG performance status (p = 1.000), and baseline presence of brain metastases (p = 0.862). The response rate was 47.8%, and disease control was 95.6%. The 12-month progression-free survival (PFS) and overall survival (OS) rates were 85.3% and 86.5%, respectively, while the 60-month PFS rate was not reached, and the 60-month OS rate was 27.1%. The mPFS and mOS were 32 months. Conclusions: The results of this analysis are promising, as our patients experienced better outcomes compared to those in the ALTA 1L study, which may be attributed to the small sample size. However, the effectiveness of brigatinib has been confirmed in our clinical practice.

Keywords: ALK-positive; NSCLC; OS; PFS; brigatinib.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
(a) The Kaplan–Meier curve for mPFS for whole group of patients, displayed in months (32.0 months), and (b) the Kaplan–Meier curve for mOS for all patients treated with brigatinib, displayed in months (32.0 months).
Figure 2
Figure 2
(a) The Kaplan–Meier curve for mPFS for patients treated with brigatinib in first-line setting, displayed in months (44.8 months), and (b) the Kaplan–Meier curve for mOS for patients treated with brigatinib in first-line setting, displayed in months (32.0 months).
Figure 3
Figure 3
PFS and OS for each of 5 patients treated with brigatinib in further therapy lines, displayed in months (39.0 and 33.0 months, respectively).
See this image and copyright information in PMC

References

    1. Filho A.M., Laversanne M., Ferlay J., Colombet M., Piñeros M., Znaor A., Parkin D.M., Soerjomataram I., Bray F. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int. J. Cancer. 2025;156:1336–1346. doi: 10.1002/ijc.35278. - DOI - PubMed
    1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H., Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002;346:92–98. doi: 10.1056/NEJMoa011954. - DOI - PubMed
    1. Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014;371:2167–2177. doi: 10.1056/NEJMoa1408440. Erratum in N. Engl. J. Med. 2015, 373, 1582. - DOI - PubMed
    1. Camidge D.R., Kim D.W., Tiseo M., Langer C.J., Ahn M.J., Shaw A.T., Huber R.M., Hochmair M.J., Lee D.H., Bazhenova L.A., et al. Exploratory Analysis of Brigatinib Activity in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J. Clin. Oncol. 2018;36:2693–2701. doi: 10.1200/JCO.2017.77.5841. - DOI - PubMed
    1. Costa D.B., Shaw A.T., Ou S.H., Solomon B.J., Riely G.J., Ahn M.J., Zhou C., Shreeve S.M., Selaru P., Polli A., et al. Clinical Experience with Crizotinib in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J. Clin. Oncol. 2015;33:1881–1888. doi: 10.1200/JCO.2014.59.0539. - DOI - PMC - PubMed

LinkOut - more resources